Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy
Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage...
Deals
Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915
Johnson & Johnson (J&J, NYSE: JNJ) announced a definitive agreement to acquire Halda Therapeutics in an all‑cash...
Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced plans to de‑register and cancel its U.S. subsidiary,...
MSD Acquires Cidara Therapeutics in $9.2‑Billion Deal to Expand Antiviral Portfolio
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics, Inc....
BrightGene Boosts Stake in Geek Gene to 12.8% with RMB 50 M Injection – Expanding Cell‑Therapy Portfolio
BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB 50 million (≈ US$7.2 million) capital increase...
Adagene Licenses SAFEbody Platform to Third Arc Bio for Masked CD3 T‑Cell Engagers
Adagene Inc. (NASDAQ: ADAG) and Third Arc Bio, Inc. announced today that they have signed...
Pfizer Reduces BioNTech Holding by 54.7% While Collaboration Remains Intact
Pfizer Inc. (NYSE: PFE) disclosed on November 13, 2025 that it has sold a portion of its...
EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz
EirGenix Inc. (TPE: 6589) announced a second, worldwide exclusive licensing agreement with Sandoz AG (SWX:...
Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion
Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...
Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform
Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...
Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders
Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...
Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research
Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...
AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs
AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...
ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing
Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...
Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers
Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...
Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced
Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....
GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies
GemPharmatech Inc., (SHA: 688046) a global leader in pre‑clinical research solutions and genetically‑engineered mouse models,...
Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology
Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing...
Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....
Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...